
|Videos|August 9, 2016
Melisa Wong on Factors That Affect Lung Cancer Treatment
Author(s)Melisa Wong, MD
Melisa Wong, MD, Oncology Chief Fellow, Hematology/Oncology, Aging Research T32 Fellow, University of California San Francisco Geriatrics, discusses the impact that comorbidities have on the treatment for lung cancer.
Advertisement
Melisa Wong, MD, Oncology Chief Fellow, Hematology/Oncology, Aging Research T32 Fellow, University of California San Francisco Geriatrics, discusses the impact that comorbidities have on the treatment for lung cancer.
In her study, Wong found that patients with comorbidities were 40% less likely to be treated for distant recurrence, yet this disparity did not exist for local-regional disease. Wong says that this is a topic that she would like to explore further.
Advertisement
Related Content
Advertisement




First-Line Treatment Choice and Altering Resistance in EGFR-Mutant NSCLC
Published: | Updated:

Latest CME
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Zanidatamab-hrii in GEA: Key Takeaways for Oncology Nurses
2
Managing Daraxonrasib: Key Takeaways and Efficacy Insights for Oncology Nurses
3
Addressing Financial Toxicity: Team-Based Workflows in Oncology Care
4
Early Amivantamab Experience and Subcutaneous Dosing in COPERNICUS
5












































